Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-18 08:00 |
Biophytis annonce ses résultats financiers 2022 et ses perspectives 2023
|
French | 288.2 KB | ||
| 2023-04-17 23:00 |
Résultats de l’Assemblée Générale Mixte du 17 avril 2023
|
French | 203.1 KB | ||
| 2023-03-30 23:00 |
L’Assemblée Générale mixte se tiendra en seconde convocation le 17 avril 2023
|
French | 176.5 KB | ||
| 2023-03-27 08:00 |
Biophytis a présenté Sarconeos (BIO101) comme potentiel candidat médicament dan…
|
French | 215.2 KB | ||
| 2023-03-20 08:00 |
Biophytis présente le développement de Sarconeos (BIO101) en tant que candidat-…
|
French | 188.1 KB | ||
| 2023-03-17 08:00 |
Biophytis annonce un changement de ratio pour son programme d'American Deposita…
|
French | 182.1 KB | ||
| 2023-03-09 08:00 |
Biophytis présente les résultats positifs de Phase 2-3 COVA à la 21ème Confére…
|
French | 202.3 KB | ||
| 2023-03-02 08:13 |
Biophytis annonce la signature d’un accord-cadre avec Intsel Chimos, laboratoir…
|
French | 212.4 KB | ||
| 2023-03-02 08:00 |
• Biophytis et Intsel Chimos ont signé un accord-cadre qui prévoit qu’Intsel Ch…
|
French | 212.4 KB | ||
| 2023-02-27 08:00 |
Biophytis démarre le processus règlementaire de demande d’autorisation d’accès …
|
French | 216.8 KB | ||
| 2023-02-23 08:00 |
Biophytis annonce la convocation d’une assemblée générale mixte le 30 mars 2023
|
French | 138.9 KB | ||
| 2023-02-02 08:00 |
Biophytis annonce les résultats finaux positifs de son étude COVA de phase 2-3…
|
French | 166.2 KB | ||
| 2023-01-31 08:00 |
Biophytis publie ses résultats financiers du 1er semestre 2022
|
French | 361.2 KB | ||
| 2023-01-19 08:00 |
Arrêt de la Cour d'appel de Paris du 17 janvier 2023 dans l'affaire opposant Bi…
|
French | 107.2 KB | ||
| 2023-01-12 09:55 |
Biophytis prévoit de prendre les mesures appropriées après avoir reçu l’avis d…
|
French | 196.9 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
